GlassScriptPhysician profile
Peter R Kvapil
NPI 1023093481
$16,488.37
in general payments reported to CMS, 2019-2025
46 companies · $2,770 in 2025
The $2,770 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,263 · 2020: $471 · 2021: $1,360 · 2022: $3,059 · 2023: $3,126 · 2024: $3,440 · 2025: $2,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,316 · Education: $19.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,316.31 |
| Education | $19.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,397.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,336.38 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $1,301.96 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $825.86 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $732.02 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $731.05 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $569.46 | 2019-2024 | Dificid, Zinplava |
| Gilead Sciences, INC. | $543.57 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $497.03 | 2021-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $479.96 | 2019-2023 | Stelara, Remicade, Tremfya |
| Phathom Pharmaceuticals, INC. | $378.52 | 2024-2025 | Voquezna |
| Pfizer INC. | $355.77 | 2019-2025 | |
| Medtronic, INC. | $297.54 | 2022-2025 | Pillcam |
| Genzyme Corporation | $279.00 | 2024-2025 | |
| Ardelyx, INC. | $277.53 | 2022-2025 | Ibsrela |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $277.11 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $255.69 | 2019-2023 | Rebyota |
| Lilly USA, LLC | $235.94 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $194.03 | 2022-2025 | Dupixent |
| Vivus LLC | $181.14 | 2021-2024 | Qsymia, Pancreaze |
| Intercept Pharmaceuticals, INC. | $163.65 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $126.58 | 2021-2023 | |
| Pentax of America, INC. | $115.02 | 2023 | C2 Cryoballoon |
| Aimmune Therapeutics, INC. | $97.12 | 2024-2025 | Vowst |
| Capsovision, INC. | $93.80 | 2024 | Capsocam Plus |
| Braintree Laboratories, INC. | $66.99 | 2019-2023 | Sutab |
| Ironwood Pharmaceuticals, INC | $62.64 | 2020-2023 | Linzess |
| Boston Scientific Corporation | $60.51 | 2019-2024 | Resolution 360 Ultra Clip |
| Celltrion USA INC. | $54.30 | 2024-2025 | Vegzelma, Zymfentra |
| Sandoz INC. | $49.34 | 2023 | Hyrimoz |
| Redhill Biopharma INC. | $46.87 | 2020-2022 | |
| Conmed Corporation | $45.45 | 2023 | Airseal |
| Daiichi Sankyo INC. | $40.89 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $35.17 | 2019 | |
| Madrigal Pharmaceuticals | $34.66 | 2025 | Rezdiffra |
| Shire North American Group INC | $33.21 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $30.36 | 2025 | Iqirvo |
| Lucid Diagnostics INC. | $27.81 | 2022 | |
| Enterra Medical, INC. | $24.48 | 2023 | |
| Evoke Pharma, INC. | $21.84 | 2023 | Gimoti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.53 | 2023 | Cyltezo |
| Ucb, INC. | $19.66 | 2019 | |
| Exact Sciences Corporation | $18.45 | 2023 | Cologuard Collection Kit |
| Ethicon US, LLC | $17.94 | 2019 | |
| Covidien LP | $17.89 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kvapil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.